5,5-dimethyl-3-((1R,4R)-4-((3-nitropyridin-4-yl)amino)cyclohexyl)-4-phenyloxazolidin-2-one | 1437789-82-6

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 英文名称: 5,5-dimethyl-3-((1R,4R)-4-((3-nitropyridin-4-yl)amino)cyclohexyl)-4-phenyloxazolidin-2-one
• CAS: 1437789-82-6
• 化学式: C₂₂H₂₆N₄O₄
• 分子量: 410.473
• InChiKey: MMAIQZBRNLIZTL-ZWOKBUDYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.69
• 重原子数：
  30.0
• 可旋转键数：
  5.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  97.6
• 氢给体数：
  1.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  5,5-dimethyl-3-((1R,4R)-4-((3-nitropyridin-4-yl)amino)cyclohexyl)-4-phenyloxazolidin-2-one 在 肼 作用下， 以 乙醇 、 水 为溶剂， 反应 3.0h， 以100%的产率得到(S)-5,5-dimethyl-3-(4-((3-nitropyridin-4-yl)amino)cyclohexyl)-4-phenyloxazolidin-2-one
  参考文献：
  名称：

  Discovery of Novel, Induced-Pocket Binding Oxazolidinones as Potent, Selective, and Orally Bioavailable Tankyrase Inhibitors

  摘要：

  Tankyrase (TNKS) is a poly-ADP-ribosylating protein (PARP) whose activity suppresses cellular axin protein levels and elevates beta-catenin concentrations, resulting in increased oncogene expression. The inhibition of tankyrase (TNKS1 and 2) may reduce the levels of beta-catenin-mediated transcription and inhibit tumorigenesis. Compound 1 is a previously described moderately potent tankyrase inhibitor that suffers from poor pharmacokinetic properties. Herein, we describe the utilization of structure-based design and molecular modeling toward novel, potent, and selective tankyrase inhibitors with improved pharmacokinetic properties (39, 40).

  DOI：

  10.1021/jm4000038
• 作为产物：
  描述：

  (S)-(+)-2-苯甘氨酸甲酯 盐酸盐 在 三乙胺 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 1,2-二氯乙烷 、 乙腈 为溶剂， 反应 3.25h， 生成 5,5-dimethyl-3-((1R,4R)-4-((3-nitropyridin-4-yl)amino)cyclohexyl)-4-phenyloxazolidin-2-one
  参考文献：
  名称：

  Discovery of Novel, Induced-Pocket Binding Oxazolidinones as Potent, Selective, and Orally Bioavailable Tankyrase Inhibitors

  摘要：

  Tankyrase (TNKS) is a poly-ADP-ribosylating protein (PARP) whose activity suppresses cellular axin protein levels and elevates beta-catenin concentrations, resulting in increased oncogene expression. The inhibition of tankyrase (TNKS1 and 2) may reduce the levels of beta-catenin-mediated transcription and inhibit tumorigenesis. Compound 1 is a previously described moderately potent tankyrase inhibitor that suffers from poor pharmacokinetic properties. Herein, we describe the utilization of structure-based design and molecular modeling toward novel, potent, and selective tankyrase inhibitors with improved pharmacokinetic properties (39, 40).

  DOI：

  10.1021/jm4000038

文献信息

• OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF
  申请人：AMGEN INC.

  公开号：US20150045368A1

  公开（公告）日：2015-02-12

  Compounds of Formula (I) and Formula (II) are useful inhibitors of tankyrase. Compounds of Formula (I) and Formula (II) have the following structure: where the definitions of the variables are provided herein.

  式(I)和式(II)的化合物是坦克酰酶的有用抑制剂。式(I)和式(II)的化合物具有以下结构：其中变量的定义在此提供。
• US9340549B2
  申请人：——

  公开号：US9340549B2

  公开（公告）日：2016-05-17